RegenxBio and Rocket Signs Exclusive Worldwide License Agreement for NAV AAV9 Vector

 RegenxBio and Rocket Signs Exclusive Worldwide License Agreement for NAV AAV9 Vector

RegenxBio and Rocket Signs Exclusive Worldwide License Agreement for NAV AAV9 Vector

Shots:

  • RegenxBio to receive $7M upfront, milestones payments plus royalties on net sales. Rocket to get exclusive worldwide rights for RegenxBio’s NAV AAV9 Vector to develop and commercialize gene therapies for Danon disease
  • Rocket also has exclusive option to add two additional NAV AAV vectors for Danon disease, for duration of four years
  • REGENXBIO’s NAV Technology Platform is an adeno-associated virus (AAV) gene delivery system, used for developing gene therapy in multiple therapeutic areas

Click here to read full press release/ article | Ref: RegenxBio | Image: Pharma Journalist

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post